Reference : Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic s...
Scientific journals : Article
Human health sciences : Hematology
Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia : a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation
Baron, Frédéric mailto [Université de Liège - ULiège > > GIGA-R : Hématologie >]
Labopin, M. []
Niederwieser, D. []
Vigouroux, S. []
Cornelissen, JJ. []
Malm, C. []
Vindelov, LL. []
Blaise, D. []
Janssen, JJWM []
Petersen, E. []
Socié, G. []
Nagler, A. []
Rocha, V. []
Mohty, M. []
Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Nature Publishing Group
Yes (verified by ORBi)
United Kingdom
[en] reduced-intensity conditioning ; AML ; GVHD ; chronic ; graft-versus-leukemia effects
[en] This report investigated the impact of graft-versus-host disease (GVHD) on transplantation outcomes in 1859 acute myeloid leukemia patients given allogeneic peripheral blood stem cells after reduced-intensity conditioning (RIC allo-SCT). Grade I acute GVHD was associated with a lower risk of relapse (hazards ratio (HR)¼0.7, P¼0.02) translating into a trend for better overall survival (OS; HR¼1.3; P¼0.07). Grade II acute GVHD had no net impact on OS, while grade III–IV acute GVHD was associated with a worse OS (HR¼0.4, Po0.0.001) owing to high risk of nonrelapse mortality (NRM; HR¼5.2, Po0.0001). In time-dependent multivariate Cox analyses, limited chronic GVHD tended to be associated with a lower risk of relapse (HR¼0.72; P¼0.07) translating into a better OS (HR¼1.8; Po0.001), while extensive chronic GVHD was associated with a lower risk of relapse (HR¼0.65; P¼0.02) but also with higher NRM (HR¼3.5; Po0.001) and thus had no net impact on OS. In-vivo T-cell depletion with antithymocyte globulin (ATG) or alemtuzumab was successful at preventing extensive chronic GVHD (Po0.001), but without improving OS for ATG and even with worsening OS for alemtuzumab (HR¼0.65; P¼0.001). These results highlight the role of the immune-mediated graft-versus-leukemia effect in the RIC allo-SCT setting, but also the need for improving the prevention and treatment of severe GVHD.

File(s) associated to this reference

Fulltext file(s):

Open access
leu2012135a_prepublished.pdfPublisher postprint443.18 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.